These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29590134)

  • 1. Patient preferences for Interferon-beta in Iran: A discrete choice experiment.
    Rahimi F; Rasekh HR; Abbasian E; Peiravian F; Etemadifar M; Ashtari F; Sabzghabaee AM; Amirsadri MR
    PLoS One; 2018; 13(3):e0193090. PubMed ID: 29590134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
    Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
    Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis.
    Shingler SL; Swinburn P; Ali S; Perard R; Lloyd AJ
    J Med Econ; 2013 Aug; 16(8):1036-42. PubMed ID: 23730944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE.
    Poulos C; Kinter E; van Beek J; Christensen K; Posner J
    Int J Technol Assess Health Care; 2018 Jan; 34(4):425-433. PubMed ID: 30251947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
    Bottomley C; Lloyd A; Bennett G; Adlard N
    J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient preference for a long-acting recombinant FSH product in ovarian hyperstimulation in IVF: a discrete choice experiment.
    van den Wijngaard L; Rodijk IC; van der Veen F; Gooskens-van Erven MH; Koks CA; Verhoeve HR; Mol BW; van Wely M; Mochtar MH
    Hum Reprod; 2015 Feb; 30(2):331-7. PubMed ID: 25432926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment.
    Bandari D; Adamson M; Bowman M; Gutierrez A; Athavale A; Oak B; Hadker N; Branco F; Geremakis C; Lewin JB; Shankar SL
    J Med Econ; 2023; 26(1):1507-1518. PubMed ID: 37934412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Patient-Centered Care by Assessing Patient Preferences for Multiple Sclerosis Disease-Modifying Agents: A Stated-Choice Experiment.
    Carlin CS; Higuera L; Anderson S
    Perm J; 2017; 21():16-102. PubMed ID: 28406788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new approach to pharmaceutical pricing based on patients' willingness to pay.
    Rahimi F; Rasekh HR; Abbasian E; Peiravian F
    Trop Med Int Health; 2018 Dec; 23(12):1326-1331. PubMed ID: 30286256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of beta-interferon in the treatment of multiple sclerosis: high-rate injectable dose therapy].
    Demina TL; Khachanova NV; Davydovskaia MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(5):76-9. PubMed ID: 15952547
    [No Abstract]   [Full Text] [Related]  

  • 11. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion of interferon beta in Iran and its utilization in Tehran.
    Palesh M; Jonsson PM; Jamshidi H; Wettermark B; Tomson G; Fredrikson S
    Pharmacoepidemiol Drug Saf; 2008 Sep; 17(9):934-41. PubMed ID: 18509835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment.
    Harrison M; Marra C; Shojania K; Bansback N
    Rheumatology (Oxford); 2015 Oct; 54(10):1816-25. PubMed ID: 25989956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.
    Saiz A; Mora S; Blanco J;
    Neurologia; 2015 May; 30(4):214-22. PubMed ID: 24484756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis.
    Webb EJD; Meads D; Eskyte I; King N; Dracup N; Chataway J; Ford HL; Marti J; Pavitt SH; Schmierer K; Manzano A
    Patient; 2018 Aug; 11(4):391-402. PubMed ID: 29313265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of falling reimbursement rates on physician preferences regarding drug therapy for osteoarthritis using a discrete choice experiment.
    Berchi C; Degieux P; Halhol H; Danel B; Bennani M; Philippe C
    Int J Pharm Pract; 2016 Apr; 24(2):114-22. PubMed ID: 26383231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
    Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countries.
    Visser LA; Huls SPI; Uyl-de Groot CA; de Bekker-Grob EW; Redekop WK
    J Neurol Sci; 2021 Sep; 428():117587. PubMed ID: 34364148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.